New synthetic thrombin inhibitors: Molecular design and experimental verification

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Sinauridze, Elena I ^a,c   Romanov, Alexey N ^b   Gribkova, Irina V ^a,c   Kondakova, Olga A ^b   Surov, Stepan S ^c   Gorbatenko, Aleksander S ^a   Butylin, Andrey A ^a,b   Monakov, Mikhail Yu ^a   Bogolyubov, Alexey A ^d   Kuznetsov, Yuryi V ^d   Sulimov, Vladimir B ^b,e   Ataullakhanov, Fazoyl I ^a,b,c  

^a NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

^c CENTER FOR THEORETICAL PROBLEMS OF PHYSICOCHEMICAL PHARMACOLOGY   (Russian Federation)

^d RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

^e Dimonta Ltd   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOTHIAZOLINIUM DERIVATIVE; 4 AMINOPYRIDINIUM DERIVATIVE; ARGATROBAN; NSC 1123477; NSC 123477; NSC 305831; NSC 328131; NSC 41339; NSC 4482; THIOUREA DERIVATIVE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; ANTITHROMBIN; THROMBIN;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; AQUEOUS SOLUTION; ARTICLE; AUTOCLAVE; COMPUTER AIDED DESIGN; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; GENETIC ALGORITHM; HEMODILUTION; HUMAN; HYPERCOAGULABILITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; LD 50; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; RAT; THROMBIN TIME; ALGORITHM; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; METHODOLOGY; SYNTHESIS; THROMBOPHILIA; THROMBOSIS;

MUS; RATTUS;

ALGORITHMS; ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; COMPUTER-AIDED DESIGN; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; RATS; THROMBIN; THROMBOPHILIA; THROMBOSIS;

EID: 79956150472     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019969     Document Type: Article

References (40)

1. Ng KFJ, Lam CCK, Chan LC, (2002) In vivo effect of hemodilution with saline on coagulation: a randomized controlled trial. B J Anaesth 88: 475-480.
2. Ruttmann TG, James MF, Aronson I, (1998) In vivo investigation into the effects of haemodilution with hydroxyethyl starch (200/0.5) and normal saline on coagulation. Br J Anaesth 80: 612-616.
3. Nisio MDi, Middeldorp S, Buller HR, (2005) Direct thrombin inhibitors. N Engl J Med 353: 1028-1040.
4. Schwarz RP, (1997) The preclinical and clinical pharmacology of Novastan (Argatroban). In: Pifarre R, editors. New Anticoagulants for the Cardiovascular Patient Philadelphia, PA, US Hanley and Belfus Inc pp. 231-249.
5. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W, (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64: 292-303.
6. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
7. Lu T, Markotan T, Coppo F, Tomczuk B, Crysler C, et al. (2004) Oxyguanidines. Part 2: discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis. Bioorg Med Chem Lett 14: 3727-3731.
8. Kawabata S, Miura T, Morita T, Kato H, Fujikawa K, et al. (1988) Highly sensitive peptide-4-methylcoumaryl-7-amide substrates for blood-clotting proteases and trypsin. Eur J Biochem 172: 17-25 S3.
9. Romanov AN, Kondakova OA, Grigoriev FV, Sulimov AV, Luschekina SV, et al. (2008) The SOL docking package for computer-aided drug design. Numerical Methods and Programming 9: 213-233 (in Russian, abstract in English) Available: http://num-meth.srcc.msu.ru/english/zhurnal/tom_2008/v9r126.html. Accessed 2011 Apr 27; http://www.keenbase.ru/file/v9r126.pdf. Accessed 2011 Apr 27.
10. Halgren TA, (1996) Merck Molecular Force Field J Comput Chem 17: 490-586 616-641.
11. Ghosh A, Rapp CS, Friesner RA, (1998) Generalized Born model based on a surface integral formulation. J Phys Chem, Sect B 102: 10983-10990.
12. Romanov AN, Jabin SN, Martynov YB, Sulimov AV, Grigoriev FV, et al. (2004) Surface generalized Born method: a simple, fast and precise implicit solvent model beyond the Coulomb approximation. J Phys Chem, Sect A 108: 9323-9327.
13. Word JM, Lovell SC, Richardson JS, Richardson DC, (1999) Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J Mol Biol 285: 1735-1747.
14. Grigoriev FV, Romanov AN, Kondakova OA, Luschekina SV, Sulimov VB, (2006) The algorithm of the force parameters placing at the atoms of organic molecules and proteins in the frame of the force field MMFF 94. Numerical Methods and Programming 7: 128-136 (in Russian) Available: http://num-meth.srcc.msu.ru/english/zhurnal/tom_2006/pdf/v7r213.pdf. Accessed 2011 Apr 27.
15. Keenbase website. Available: http://www.keenbase.ru. Accessed 2011 Apr 27.
16. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998) Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 19: 1639-1662.
17. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
18. National Cancer Institute The Open Chemical Repository Collection. Diversity Set: Developments Therapeutics Program NCI/NIH website. Available: http://www.dtp.nci.nih.gov/docs/3d_database/Structural_information/structural_data.html Accessed 2011 Apr 27.
19. Gasteiger J, Rudolph C, Sadowski J, (1990) Automatic generation of 3D-atomic coordinates for organic molecules. Tetrahedron Comput Methodol 3: 537-547.
20. Filamofitsky MP, (2004) The system X-Com for metacomputing support: architecture and technology. Numerical Methods and Programming 5: 1-9 (in Russian, abstract in English); Available: http://num-meth.srcc.msu.ru/english/zhurnal/tom_2004/v5r201.html. Accessed 2011 Apr 27.
21. Sobolev SI, (2008) Effective performance of distributed computing environments. In: Voevodin VV, Tyrtyshnikov EE, editors. Numerical methods, parallel calculations and information technologies Moscow State University Press, Moscow, Russia pp. 249-258 (in Russian).
22. Zhabin SN, Sulimov VB, TAGSS Registration program certificate No. 2006613753. 27 October 2006. FEDERAL SERVICE FOR INTELLECTUAL PROPERTY, PATENTS AND TRADEMARKS (ROSPATENT) (in Russian).
23. Lottenberg R, Christensen U, Jackson CM, Coleman PL, (1981) Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. Methods Enzymol 80PtC: 341-361.
24. Lottenberg R, Hall JA, Fenton JW 2nd, Jackson CM, (1982) The action of thrombin on peptide p-nitroanilide substrates: hydrolysis of Tos-Gly-Pro-Arg-pNA and D-Phe-Pip-Arg-pNA by human alpha and gamma and bovine alpha and beta-thrombins. Thromb Res 28: 313-332.
25. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, et al. (2002) The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 32: 249-253.
26. Sinauridze EI, Gorbatenko AS, Gribkova IV, Sulimov VB, Romanov AN, et al. (2008) Plasma dilution with artificial plasma expanders causes hypercoagulation. Technology of the Living Systems (Moscow) 5: 3-14 (in Russian, abstract in English).
27. Guide for the Care and Use of Laboratory Animals (1996) Washington DC, USA National Acad Press pp. 21-55.
28. Weil CS, (1952) Tables for convenient calculation of mediane-effective dose (LD50 or ED50) and instructions in their use. Biometrics 8: 249-263.
29. Illig C, Eisennagel S, Bone R, et al. (1998) Expanding the envelope of structure-based design using chemical libraries: Application to small-molecule inhibitors of thrombin. Med Chem Res 8: 244-260.
30. Lu T, Tomczuk B, Illig C, Bone R, Murphy L, et al. (1998) In vitro evaluation and crystallographic analysis of a new class of selective, non-amide-based thrombin inhibitors. Bioorg Med Chem Lett 8: 1595-1600.
31. Soll RM, Lu T, Tomczuk B, Illig CR, Fedde C, et al. (2000) Amidinohydrazones as guanidine bioisosteres: Application to a new class of potent, selective and orally bioavailable, non-amide-based small-molecule thrombin inhibitors. Bioorg Med Chem Lett 10: 1-4.
32. Tomczuk B, Lu T, Soll RM, Fedde C, Wang A, et al. (2003) Oxyguanidines: application to non-peptidic phenyl-based thrombin inhibitors. Bioog Med Chem Lett 13: 1495-1498.
33. Developments Therapeutics Program NCI/NIH website. Available: http://www.dtp.nci.nih.gov/branches/dscb/repo_open.html. Accessed 2011 Apr 27.
34. Sinauridze EI, Ataullakhanov FI, Butylin AA, Sulimov VB, Romanov AN, et al. (27.06.2008, priority 28.06.2007) New compounds with antithrombin function and pharmaceutical compositions based on them. International Patent Application PCT/RU2008/000400. Applicant: Bionika, Moscow, Russia.
35. Matsuo T, (2007) Argatroban. Antithrombotic Therapy in Clinical Practice. Kobe Research Projects on Thrombosis and Haemostasis. Japan. 1 p.
36. Lau A, Berry LR, Mitchell LG, Chan AKC, (2007) Effect of substrate and fibrin polymerization inhibitor on determination of plasma thrombin generation in vitro. Thromb Res 119: 667-677.
37. Nagashima H, (2002) Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and argatroban. J Biol Chem 277: 50439-50444.
38. Mano T, Shiomura J, 20.10 93 (priority 18.03.92) Argatroban preparation for ophtalmic use. European patent application. Publication number: EP 0 565 897 A1. Bulletin 93/42. Applicant: Mitsubishi Kasei Corporation, Tokyo, Japan.
39. Sinauridze EI, Gorbatenko AS, Azhigirova MA, Dereza TL, Ataullakhanov FI, (December 27, 2005) The method for correction of initial hemostasis disturbances by plasma expanders of new composition. Russian Federation Patent No 2005140841 (in Russian).
40. Sorbera LA, Bozzo J, Castaner J, (2005) Dabigatran/dabigatran etexilate. Drugs Fut 30: 877-885.